Phenotype of mesenchymal stem cells from patients with myelodyplastic syndrome maybe partly modulated by decitabine

Mesenchymal stem cells (MSCs) derived from myelodysplastic syndromes (MDSs) have been demonstrated to accelerate the progression of MDS. However, whether the phenotype of MSCs derived from MDS (MDS-MSCs) may be reversed and serve as a potential target for the treatment of MDS remains unclear. The pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Pang, Yanbin, Geng, Suxia, Zhang, Hongyang, Lai, Peilong, Liao, Pengjun, Zeng, Lingji, Lu, Zesheng, Weng, Jianyu, Du, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781515/
https://www.ncbi.nlm.nih.gov/pubmed/31611955
http://dx.doi.org/10.3892/ol.2019.10788

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781515/
https://www.ncbi.nlm.nih.gov/pubmed/31611955
http://dx.doi.org/10.3892/ol.2019.10788

Ejemplares similares